All results
2 results for randomized double blind placebo controlled study assess efficacy safety and
-
REPLENISH
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…
- Ages
- 50 Years - N/A
- Sexes
- All
-
GCAptAIN
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
- Ages
- 50 Years - N/A
- Sexes
- All